Over the last decade, CRISPR gene editing has revolutionized both practical research and the development of cell and gene therapies. The choice of the nuclease and gRNA format is often the most important element determining a successful outcome. The toolbox of available CRISPR systems has grown over the decade, offering highly specific and efficient nucleases, expanding the addressable applications and therapeutics.

In this video, Casey Jowdy, Senior Product Manager at Synthego, will describe a high fidelity Cas12 variant, hfCas12Max, and demonstrate a variety of applications where hfCas12Max performs superiorly to traditional Cas nucleases. Additionally, he will discuss how the hfCas12Max CRISPR system complements Synthego's industry-leading RUO-to-GMP continuum for the development of CRISPR-based therapeutics.

Don't miss out on this opportunity to learn more about:

  • The engineering and optimization of the hfCas12Max variant
  • Applications where hfCas12Max performs superiorly to traditional Cas nucleases
  • Current and future opportunities for the use of hfCas12Max in CRISPR-based therapeutics